Innovative Cell Technologies AM105-500 Accumax Cell Dissociation Solution 500 ml $178 Innovative Cell Technologies AT104 Accutase in Action 100 ml $18 Innovative Cell Technologies AT104-500 Accutase in Action 500 ml $72 Innovative Cell Technologies ...
Accumax Cell Dissociation Solution 100 ml $45 Innovative Cell Technologies AM105-500 Accumax Cell Dissociation Solution 500 ml $178 Innovative Cell Technologies AT104 Accutase in Action 100 ml $18 Innovative Cell Technologies AT104-500 Accutase in Action 500 ml $72 Innova...
AT104 AccutaseâCell Dissociation Solution 100 ml 一种具有蛋白水解酶和胶原水解酶活性的天然酶的混合物,同时具有yi蛋白酶和胶原酶的作用,比哺乳动物yi蛋白酶和胶原酶更有效。相同效果下,它的配方浓度更低,毒性更小,更温和 AM105 AccumaxâCell Dissociation Solution ...
产品列表:Innovative Cell Technologies代理 货号 产品 规格 简介 AT104 Accutaseâ Cell Dissociation Solution 100 ml 一种具有蛋白水解酶和胶原水解酶活性的天然酶的混合物,同时具有yi蛋白酶和胶原酶的作用,比哺乳动物yi蛋白酶和胶原酶更有效。相同效果下,它的配方浓度更低,毒性更小,更温和 AM105 Accumaxâ Cel...
Brugada syndrome: from cell to bedside. Curr. Probl. Cardiol. 30, 9–54 (2005). Article PubMed PubMed Central Google Scholar Xu, X. et al. Increasing I(Ks) corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy. Am. J. Physiol. Heart Circ. ...
Brufau MT, Martin-Venegas R, Guerrero-Zamora AM, Perez-Vendrell AM, Vila B, Brufau J, Ferrer R (2015) Dietary beta-galactomannans have beneficial effects on the intestinal morphology of chickens challenged with Salmonella enterica serovar Enteritidis. J Anim Sci 93:238–246 Article PubMed CAS ...
Baraona F, Valente AM, Porayette P, et al. Coronary arteries in childhood heart disease: Implications for management of young adults. J ClinExpCardiolog. 2012;S8:006. Aksu T, Yalin K. Substrate-guided ablation of ischemic ventricular tachycardia: Is it really necessary to induce ventricular ta...
technologies • Targeted biological know-how neutrophil • Deep understanding of novel respiratory targets • Understanding of patient phenotypes • Expertise in trial design and delivery epithelial cell eosinophil dendritic cell 42 Respiratory R&D beyond Asthma and COPD Taking our respiratory know-...
or technologies used to modulate the release of a drug in the body over time and/or target the drug to a particular tissue or cell type. The first DDS, a sustained-release system delivering dextroamphetamine, was approved in 1952 (Box2). A timeline describing the development of several key...
Carton et al., “Hypotonicity induces membrane protrusions and actin remodeling via activation of small GTPases Rac and Cdc42 in Rat-1 fibroblast,” Am. J. Physiol. Cell. Physiol., 285, C935-C944 (2003). Chernomorskii, “Diagram of the electrochemical stability of water”, Russian Jour...